Serum AKR1B10 predicts the risk of hepatocellular carcinoma – A retrospective single-center study

Zhu, Rongping; Luo, Diteng; Dong, Mingjun; Sun, Tian; Jin, Junfei

doi:10.1016/j.gastrohep.2019.06.007

Cited by 11 publications

(8 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The remaining 64 articles were fully reviewed, and 48 articles were removed (20 articles did not provide sufficient data, eight were reviews, six were case reports, two were meta-analyses, and 12 were animal or cell experiments). Overall, 16 studies, including 11 diagnostic [19][20][21][22][23][24][25][26][27][28][29] and five prognostic [30][31][32][33][34]studies, were included in our meta-analysis.…”

Section: Characteristics Of the Included Studiesmentioning

confidence: 99%

“…A total of 11 studies [19][20][21][22][23][24][25][26][27][28][29] including 12 different cohorts reported data evaluating the diagnostic accuracy of AKR1B10 for HCC, and they were published between 2014 and 2020. Data from 2747 HCC patients and 2053 controls were collected.…”

Section: Accuracy Of Akr1b10 For Diagnosing Hccmentioning

confidence: 99%

“…To verify whether different sources of AKR1B10 have different diagnostic accuracies for HCC, we analyzed the diagnostic accuracy of AKR1B10 levels for HCC in two samples. A total of five articles [19][20][21][22][23] including 6 different cohorts reported the diagnostic accuracy of AKR1B10 in serum for HCC. As shown in Table 2, the pooled sensitivity and specificity of serum AKR1B10 for the diagnosis of HCC were 0.80 (95% CI: 0.70-0.86) and 0.87 (95% CI: 0.77-0.93), respectively.…”

Section: Accuracy Of Akr1b10 For Diagnosing Hccmentioning

confidence: 99%

See 2 more Smart Citations

Clinical value of AKR1B10 in hepatocellular carcinoma: A systematic review and meta-analysis

Wang

Pei

et al. 2022

PLoS ONE

View full text Add to dashboard Cite

Background To evaluate the clinical value of Aldo-keto reductase family 1 member B10 (AKR1B10) in the diagnosis and prognosis of hepatocellular carcinoma (HCC). Methods A search of the PubMed, China Biology Medicine, Cochrane, and Embase databases was performed to conduct meta-analyses to evaluate the accuracy of AKR1B10 in diagnosing HCC and to assess the impact on prognosis of patients after curative resection of HCC. Results A total of 12 different cohorts from 11 studies including 2747 HCC patients and 2053 controls showed that the pooled specificity and the pooled sensitivity of AKR1B10 for the diagnosis of HCC were 0.78 (95% CI: 0.69–0.85) and 0.85 (95% CI: 0.77–0.90), respectively. The pooled sensitivity and specificity of serum AKR1B10 for the diagnosis of HCC were 0.80 (95% CI: 0.70–0.86) and 0.87 (95% CI: 0.77–0.93), respectively. The pooled sensitivity and specificity of AKR1B10 in malignant tumor tissue for the diagnosis of HCC were 0.78 (95% CI: 0.61–0.89) and 0.82 (95% CI: 0.69–0.90), respectively. The pooled sensitivity and specificity of AKR1B10 to distinguish HCC from benign liver disease were 0.71 (95% CI: 0.62–0.78) and 0.84 (95% CI: 0.77–0.89), respectively. The sensitivity and specificity of AKR1B10 combined with alpha fetoprotein (AFP) in the diagnosis of HCC were 0.84 (95% CI: 0.79–0.88) and 0.88 (95% CI: 0.73–0.95), respectively. The pooled sensitivity and specificity of AKR1B10 in malignant tumor tissue for the diagnosis of early-stage HCC were 0.85 (95% CI: 0.62–0.95) and 0.88 (95% CI: 0.81–0.93), respectively. A meta-analysis of five studies including 798 patients demonstrated that high AKR1B10 expression in liver malignant tumor was associated with better overall survival in patients with HCC after hepatectomy (HR = 0.54, 95% CI: 0.41–0.72, p < 0.001). Conclusions AKR1B10 exhibits a great clinical value in the diagnosis of HCC, especially for early-stage HCC, with excellent diagnostic accuracy. Furthermore, AKR1B10 expression can predict the prognosis of HCC patients after hepatic resection.

show abstract

Section: Characteristics Of the Included Studiesmentioning

confidence: 99%

Section: Accuracy Of Akr1b10 For Diagnosing Hccmentioning

confidence: 99%

Section: Accuracy Of Akr1b10 For Diagnosing Hccmentioning

confidence: 99%

See 1 more Smart Citation

Clinical value of AKR1B10 in hepatocellular carcinoma: A systematic review and meta-analysis

Wang

Pei

et al. 2022

PLoS ONE

View full text Add to dashboard Cite

show abstract

“…Aldo-keto reductase family 1 member B10 (AKR1B10) is a novel secretory protein that is overexpressed in multiple tumors, including lung cancer, breast cancer, and colorectal cancer (68,69), and is a potential diagnostic and prognostic biomarker for HCC (70)(71)(72)(73). A multicenter study (74) with 1,244 participants found that serum AKR1B10 levels were significantly increased in HCC patients compared with those in non-HCC and were associated with AFP, alanine aminotransaminase, aspartate aminotransaminase, and tumor size, but not with tumor number, vascular invasion, and TNM stage, with an AUROC of 0.896, sensitivity of 72.7%, and specificity of 95.7% for the diagnosis of HCC, and these values were better than those of AFP (AUROC 0.816, sensitivity 65.1%, and specificity 88.9%), and for ANHC cases, AKR1B10 exhibited a promising diagnostic value (AUROC 0.891, sensitivity 71.2%, and specificity 92.6%), and a similar diagnostic performance was observed in AFP-negative early-stage HCC (AUROC 0.839, sensitivity 63.4%, and specificity 90.7%).…”

Section: Akr1b10mentioning

confidence: 99%

New Blood Biomarkers for the Diagnosis of AFP-Negative Hepatocellular Carcinoma

2020

View full text Add to dashboard Cite

An early diagnosis of hepatocellular carcinoma (HCC) followed by effective treatment is currently critical for improving the prognosis and reducing the associated economic burden. Alpha-fetoprotein (AFP) is the most widely used biomarker for HCC diagnosis. Based on elevated serum AFP levels as well as typical imaging features, AFP-positive HCC (APHC) can be easily diagnosed, but AFP-negative HCC (ANHC) is not easily detected due to lack of ideal biomarkers and thus mainly reliance on imaging. Imaging for the diagnosis of ANHC is probably insufficient in sensitivity and/or specificity because most ANHC tumors are small and early-stage HCC, and it is involved in sophisticated techniques and high costs. Moreover, ANHC accounts for nearly half of HCC and exhibits a better prognosis compared with APHC. Therefore, the diagnosis of ANHC in clinical practice has been a critical issue for the early treatment and prognosis improvement of HCC. In recent years, tremendous efforts have been made to discover new biomarkers complementary to AFP for HCC diagnosis. In this review, we systematically review and discuss the recent advances of blood biomarkers for HCC diagnosis, including DNA biomarkers, RNA biomarkers, protein biomarkers, and conventional laboratory metrics, focusing on their diagnostic evaluation alone and in combination, in particular on their diagnostic performance for ANHC.

show abstract

“…As reported, AKR1B10 has been shown to be secreted via nonclassical pathway mediated by lysosome [ 10 ]. In addition, it is well known to be overexpressed in human pancreatic cancer, hepatocellular carcinoma, and lung cancer [ 2 , 8 , 11 , 12 ]. However, most studies on the effects of AKR1B10 on tumors have focused on non-gastrointestinal tumors.…”

Section: Introductionmentioning

confidence: 99%

AKR1B10 inhibits the proliferation and migration of gastric cancer via regulating epithelial-mesenchymal transition

Shao

Wu²,

et al. 2021

Aging

View full text Add to dashboard Cite

Gastric cancer (GC) is a common malignancy around the world with a poor prognosis. Aldo-keto reductase family 1 member B10 (AKR1B10) is indispensable to cancer development and progression, which has served as a diagnostic biomarker for tumors. In our study, we demonstrated that the expression of AKR1B10 in GC tissues was significantly lower compared with normal gastric tissues. Subgroup analysis showed that, according to the clinic-pathological factors, the effect of the AKR1B10 expression level on the prognosis of GC patients was significantly different. Moreover, reduced expression of AKR1B10 promoted the ability of GC cells in proliferation and migration. Furthermore, increased AKR1B10 levels resulted in the opposite trend in vitro . Moreover, AKR1B10 was correlated with epithelial-mesenchymal transition (EMT) in a significant way. In vivo experiment, knockdown of AKR1B10 promoted the growth of tumor, increased Vimentin, and E-cadherin significantly. In summary, AKR1B10 is considered as a tumor suppressor in GC and is a promising therapeutic target.

show abstract

Serum AKR1B10 predicts the risk of hepatocellular carcinoma – A retrospective single-center study

Cited by 11 publications

References 23 publications

Clinical value of AKR1B10 in hepatocellular carcinoma: A systematic review and meta-analysis

Clinical value of AKR1B10 in hepatocellular carcinoma: A systematic review and meta-analysis

New Blood Biomarkers for the Diagnosis of AFP-Negative Hepatocellular Carcinoma

AKR1B10 inhibits the proliferation and migration of gastric cancer via regulating epithelial-mesenchymal transition

Contact Info

Product

Resources

About